Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ATYR

aTyr Pharma (ATYR)

aTyr Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ATYR
DateTimeSourceHeadlineSymbolCompany
12/23/20244:48PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATYRaTyr Pharma Inc
12/23/20244:42PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATYRaTyr Pharma Inc
12/17/20248:00AMGlobeNewswire Inc.aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATYRaTyr Pharma Inc
12/12/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
12/12/20244:12PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
12/12/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATYRaTyr Pharma Inc
12/12/20244:00PMGlobeNewswire Inc.aTyr Pharma Announces the Appointment of Eric Benevich to its Board of DirectorsNASDAQ:ATYRaTyr Pharma Inc
12/10/20248:00AMGlobeNewswire Inc.aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:ATYRaTyr Pharma Inc
12/09/20248:00AMGlobeNewswire Inc.aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on FibrosisNASDAQ:ATYRaTyr Pharma Inc
11/15/20248:00AMGlobeNewswire Inc.aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on FibrosisNASDAQ:ATYRaTyr Pharma Inc
11/14/20246:51PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATYRaTyr Pharma Inc
11/07/20244:07PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATYRaTyr Pharma Inc
11/07/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATYRaTyr Pharma Inc
11/07/20244:01PMGlobeNewswire Inc.aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate UpdateNASDAQ:ATYRaTyr Pharma Inc
10/31/20248:00AMGlobeNewswire Inc.aTyr Pharma to Present at Upcoming Investor ConferencesNASDAQ:ATYRaTyr Pharma Inc
10/15/20245:01PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATYRaTyr Pharma Inc
10/08/20248:00AMGlobeNewswire Inc.aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual MeetingNASDAQ:ATYRaTyr Pharma Inc
10/02/20248:00AMGlobeNewswire Inc.aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory JournalNASDAQ:ATYRaTyr Pharma Inc
08/21/20248:00AMGlobeNewswire Inc.aTyr Pharma to Participate in September Investor ConferencesNASDAQ:ATYRaTyr Pharma Inc
08/13/20244:00PMGlobeNewswire Inc.aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update NASDAQ:ATYRaTyr Pharma Inc
08/06/20248:00AMGlobeNewswire Inc.aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical OperationsNASDAQ:ATYRaTyr Pharma Inc
07/30/20248:00AMGlobeNewswire Inc.aTyr Pharma Announces Research Study with Stanford MedicineNASDAQ:ATYRaTyr Pharma Inc
07/22/20248:00AMGlobeNewswire Inc.aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary SarcoidosisNASDAQ:ATYRaTyr Pharma Inc
06/03/20248:00AMGlobeNewswire Inc.aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”NASDAQ:ATYRaTyr Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ATYR

Your Recent History

Delayed Upgrade Clock